New drug applications approved by US FDA as of 1 - 15 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The true prevalence of benign prostatic hyperplasia (BPH) in male populations has been difficult to estimate due to the lack of a standardized definition. However, the characteristic features of BPH – abnormal proliferation of stromal and epithelial prostatic cells – become more common in men with age. The following article highlights the benefits of dutasteride/tamsulosin (Duodart®, GlaxoSmithKline), a combination treatment consisting of two drugs with complementary mechanisms of action, in patients with BPH.
In patients with nocturnal urgency secondary to overactive bladder (OAB) and low nocturnal bladder capacity, a mismatch between nocturnal urine production and bladder capacity may predict response to treatment with fesoterodine, according to a study. Symptom improvement appears to be mediated by increases in typical rather than maximum nocturnal voided volumes and be associated with improved quality of life.
Older patients with overactive bladder (OAB) appear to have increased frailty compared with individuals seeking care for other nononcologic urologic diagnosis, with frailty being a significant predictor of OAB, a study has found.
The quantity of uric acid stones has significantly increased in recent decades, according to a recent study. There are proportionately more female calcium stone formers but not uric acid stone formers with time. Furthermore, the most prominent factor distinguishing uric acid from calcium stones is urinary pH.